<i>NCAPG2</i> Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma

<i>NCAPG2</i> Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma

Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), but resistance inevitably develops as the disease progresses. Erlotinib resistance and cancer stem cells (CSCs) are poor factors hindering the prognosis of patients with lung adenocar...

Full description

Bibliographic Details
Main Authors: Shiyao Jiang, Jingjing Huang, Hua He, Yueying Liu, Lu Liang, Xiaoyan Sun, Yi Li, Li Cong, Bei Qing, Yiqun Jiang
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
erlotinib resistance
cancer stem cells
lung adenocarcinoma
tumor microenvironment
<i>NCAPG2</i>
Online Access:https://www.mdpi.com/2072-6694/14/18/4395

Internet

https://www.mdpi.com/2072-6694/14/18/4395

Similar Items